$Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience$

Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience

Aim:Despite dramatic progress in the treatment of pediatric solid tumors in the last 3 decades, confronting a relapsed or refractory patient is still challenging. We report our experience of refractory/relapsed pediatric solid tumor patients treated with vincristin + topotecan + cyclophosphamide (VT...

Full description

Bibliographic Details
Main Authors:	Uğur Demirsoy, Funda Çorapçıoğlu, Meriban Karadoğan
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2019-09-01
Series:	Journal of Pediatric Research
Subjects:	Refractory solid tumors salvage chemotherapy VTC treatment
Online Access:	http://jpedres.org/archives/archive-detail/article-preview/results-of-vincristine-cyclophosphamide-and-topote/30527

Similar Items

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
by: Piotr J. Wysocki, et al.
Published: (2023-02-01)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
by: Cesar Gentille, et al.
Published: (2022-07-01)

Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma
by: Yu Yang, et al.
Published: (2023-04-01)

A review of treatment options employed in relapsed/refractory AML
by: Mohamed Zakee Mohamed Jiffry, et al.
Published: (2023-12-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Mohammadali Mashhadi, et al.
Published: (2011-09-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Behrooz Najafi, et al.
Published: (2011-10-01)

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?
by: Radhika Takiar, et al.
Published: (2022-07-01)

Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy
by: Alain Antoine Mina, et al.
Published: (2019-03-01)

Ascorbate-deficient vtc2 mutants in Arabidopsis do not exhibit decreased growth
by: Benson Lim, et al.
Published: (2016-07-01)

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
by: Norbert Grzasko, et al.
Published: (2021-11-01)

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-03-01)

Precision medicine in relapsed or refractory pediatric solid tumors: a collaborative Spanish initiative
by: Pablo Gargallo, et al.
Published: (2019-07-01)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
by: Aleksandra Wieczorek, et al.
Published: (2023-02-01)

Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
by: Harry Ross Powers, et al.
Published: (2014-09-01)

FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center
by: Şebnem Yılmaz Bengoa, et al.
Published: (2017-02-01)

Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China
by: Liu X, et al.
Published: (2019-09-01)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
by: Nikhil Yegya-Raman, et al.
Published: (2023-03-01)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
by: Suying Lu, et al.
Published: (2022-03-01)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
by: Marc-Andrea Baertsch, et al.
Published: (2021-09-01)

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
by: Ramy Rahmé, et al.
Published: (2024-01-01)

FLAG with Bortezomib Salvage Therapy in Relapsed/Refractory Childhood Leukemia—A Reliable Bridge to Transplantation with Limited Toxicity
by: Sreedhar Jayakrishnan Cherulil, et al.

Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
by: Kyoichi Kaira, et al.
Published: (2021-10-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
by: Bogdan Popescu, et al.
Published: (2019-12-01)

Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study
by: Yu Yagi, et al.
Published: (2023-09-01)

Localization data of the T-DNA insertion site in Arabidopsis line SALK_146824C
by: Elena Belykh, et al.
Published: (2024-06-01)

OTRA Based Piece-Wise Linear VTC Generators and Their Application in High-Frequency Sinusoid Generation
by: Sirish Oruganti, et al.
Published: (2017-01-01)

Intra-arterial chemotherapy in refractory and advanced intraocular retinoblastoma
by: Namita Kumari, et al.
Published: (2023-01-01)

Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL)
by: Fatma Abbas, et al.
Published: (2022-04-01)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
by: Jia Yin, et al.
Published: (2021-09-01)

Movilidad urbana, cambios en las preferencias de los usuarios en España después del COVID-19
by: Miguel Guillén-Pujadas, et al.
Published: (2023-11-01)

Advanced Solid Geopolymer Formulations for Refractory Applications
by: Shaik Hussain, et al.
Published: (2024-03-01)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
by: Leonard Jeff Harris, et al.
Published: (2020-11-01)

Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
by: Zhu X, et al.
Published: (2021-03-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
by: Xiwen Tong, et al.
Published: (2023-08-01)

Importance of polyphosphate in the Leishmania life cycle
by: Kid Kohl, et al.
Published: (2018-06-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
by: Donghao Xu, et al.
Published: (2022-03-01)